Skip to main content

VYCOR MEDICAL INC

corporate_fare Company Profile

VYCOR MEDICAL INC

VYCO·OTC·Industrial Applications And Services·CIK 0001424768

Vycor Medical, Inc. provides innovative surgical and therapeutic solutions within the medical device industry, operating two distinct business units. Vycor Medical designs, develops, and markets medical devices for neurosurgery. Its key product, the ViewSite Brain Access System ("VBAS"), is a next-generation retraction and access system. Vycor Medical holds ISO 13485:2016 and MDSAP certifications, and VBAS has U.S. FDA 510(k) clearance and CE Marking for Europe (MDD Class III) for brain and spine surgeries, along with regulatory approvals in other international markets. The second business unit, NovaVision, offers non-invasive, computer-based rehabilitation therapies for individuals with vision disorders caused by neurological brain damage, such as from a stroke. Both businesses utilize minimally or non-invasive approaches. The company was formed on June 17, 2005, as Vycor Medical LLC, converted to a Delaware corporation on August 14, 2007, and changed its name to Vycor Medical, Inc. Its listing became effective in February 2009. On November 29, 2010, Vycor acquired substantially all assets of NovaVision, Inc., and on January 4, 2012, through its NovaVision subsidiary, acquired all shares of Sight Science Limited.

VYCOR MEDICAL INC (OTC:VYCO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors VYCO SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Vycor Medical Reports Q1 Profitability & Positive Cash Flow Amidst Going Concern Doubt
  • Vycor Medical Reports 17% Revenue Growth, Achieves Operating Profit in 2025
  • VYCOR MEDICAL Issues Going Concern Warning, Cites Material Weakness in Internal Controls

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.86M
Net Income
-$72.43K
Diluted EPS
-$0.01
Op. Cash Flow
-$13.47K
Free Cash Flow
-$18.7K
Gross Profit
$1.56M
Operating Income
$33.9K
Cash & Equivalents
$86.98K
Total Debt
$135.83K
Debt / Equity
-0.03×
Net Margin
-3.9%
Shares Outstanding
33.37M sh
Source: 10-K · filed 2026-03-31 · accession 0001493152-26-014036
Browse all tickers starting with V →
$0.0698
52-week range · as of 2026-05-15 $0.0321 – $0.50
Market cap
$2.33M
Volume
7.8K (0.4× avg)
3-mo avg 19.9K
Live data · 2026-06-14 06:09 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VYCO - Latest Insights

VYCO
May 15, 2026, 2:53 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.0699
Real-time Price: $0.0698 info
Change: -$0.0001 (-0.14%) info
Market Cap: $2.329M info
VYCO
Mar 31, 2026, 3:31 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.090
Real-time Price: $0.0698 info
Change: -$0.0202 (-22%) info
Market Cap: $2.329M info
VYCO
Mar 31, 2026, 2:35 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.090
Real-time Price: $0.0698 info
Change: -$0.0202 (-22%) info
Market Cap: $2.329M info